Melbourne Theranostic Innovation Centre is pleased to announce the completion of the investigator-initiated clinical trial ‘A Single-Arm Comparative Imaging study of 68Ga-NTA-476 PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men with Prostate Cancer”, which was led by Professor Rodney Hicks as the Principal Investigator.
Within several weeks of activating the trial, MTIC had fully scheduled and allocated the dosing & imaging slots for ten prospective participants. The entire Phase I diagnostic imaging study was completed in three months from site activation.
As a research and patient driven centre, MTIC’s nimbleness and our team’s drive to bring promising new diagnostic and therapeutic radiopharmaceuticals to patients with unmet needs leads us to focus on each clinical study with dedication and scientific rigor.
We are proud of the fact that sponsors from all over the world have trusted us to serve as a site for their Phase I, II, and III clinical trials (often as the lead site).
Please contact us to learn more about our capabilities in research studies involving diagnostic and therapeutic radiopharmaceuticals.For this recently completed study on 68Ga-NTA-476, we want to first thank 3B Pharmaceuticals GmbH for their support. 3B is comprised of a great group of people, and MTIC looks forward to working on future research studies with them.
.jpg)